Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue

Cancer Letters

Volumn 246, Issue 1-2, 2007, Pages 253-261

  Spizzo, Gilbert ^a,b   Gastl, Guenther ^a,b   Obrist, Peter ^c   Fong, Dominic ^a,b   Haun, Margot ^a   Grünewald, Kurt ^a   Parson, Walther ^a   Eichmann, Cordula ^a   Millinger, Simone ^a   Fiegl, Heidi ^a   Margreiter, Raimund ^b   Amberger, Albert ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b TYROLEAN CANCER RESEARCH INSTITUTE   (Austria)

^c MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

5 Aza 2 deoxycytidine; Breast cancer; Ep CAM; Methylation; MethyLight

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; EPITHELIAL CELL ADHESION MOLECULE;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TISSUE; CONTROLLED STUDY; DEMETHYLATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; TECHNOLOGY;

ANTIGENS, NEOPLASM; AZACITIDINE; BREAST; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; COLON; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTESTINAL MUCOSA; PROMOTER REGIONS (GENETICS); RNA, MESSENGER;

EID: 33845606326     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.03.002     Document Type: Article

References (36)

1. Litvinov S.V., Bakker H.A., Gourevitch M.M., Velders M.P., and Warnaar S.O. Evidence for a role of the epithelial glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell Adhes. Commun. 2 (1994) 417-428
2. Litvinov S.V., Velders M.P., Bakker H.A., Fleuren G.J., and Warnaar S.O. Ep-CAM: a human epithelial antigen is a homophilic cell-cell adhesion molecule. J. Cell Biol. 125 (1994) 437-446
3. Balzar M., Winter M.J., de Boer C.J., and Litvinov S.V. The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med. 77 (1999) 699-712
4. Strnad J., Hamilton A.E., Beavers L.S., Gamboa G.C., Apelgren L.D., Taber L.D., et al. Molecular cloning and characterization of a human adenocarcinoma/epithelial cell surface antigen complementary DNA. Cancer Res. 49 (1989) 314-317
5. Spurr N.K., Durbin H., Sheer D., Parkar M., Bobrow L., and Bodmer W.F. Characterization and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUAI. Int. J. Cancer 38 (1986) 631-636
6. Durbin H., Rodrigues N., and Bodmer W.F. Further characterization, isolation and identification of the epithelial cell-surface antigen defined by monoclonal antibody AUA1. Int. J. Cancer 45 (1990) 562-565
7. Calabrese G., Crescenzi C., Morizio E., Palka G., Guerra E., and Alberti S. Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization. Cytogenet. Cell Genet. 92 (2001) 164-165
8. Poczatek R.B., Myers R.B., Manne U., Oelschlager D.K., Weiss H.L., Bostwick D.G., and Grizzle W.E. Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J. Urol. 162 (1999) 1462-1466
9. Litvinov S.V., van Driel W., van Rhijn C.M., Bakker H.A., van Krieken H., Fleuren G.J., and Warnaar S.O. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J. Pathol. 148 (1996) 865-875
10. Gastl G., Spizzo G., Obrist P., Dunser M., and Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356 (2000) 1981-1982
11. Spizzo G., Obrist P., Ensinger C., Theurl I., Dunser M., Ramoni A., et al. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int. J. Cancer 98 (2002) 883-888
12. Spizzo G., Went P., Dirnhofer S., Obrist P., Simon R., Spichtin H., et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res. Treat. 86 (2004) 207-213
13. Osta W.A., Chen Y., Mikhitarian K., Mitas M., Salem M., Hannun Y.A., et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res. 64 (2004) 5818-5824
14. Munz M., Kieu C., Mack B., Schmitt B., Zeidler R., and Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23 (2004) 5748-5758
15. Gutzmer R., Li W., Sutterwala S., Lemos M.P., Elizalde J.I., Urtishak S.L., et al. A tumour-associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells. J. Immunol. 173 (2004) 1023-1032
16. Ragnhammar P., Blomgren H., Edler D., Lundell G., Magnusson I., and Sonnenfeld T. Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma. Eur. J. Cancer 31A (1995) 315-320
17. Riethmuller G., Holz E., Schlimok G., Schmiegel W., Raab R., Hoffken K., et al. Monoclonal antibody therapy for resected dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J. Clin. Oncol. 16 (1998) 1788-1794
18. Punt C., Nagy A., Douillard J., Figer A., Skovsgaard T., Monson J., et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 360 (2002) 671
19. Thurmond L.M., Stimmel J.B., Ingram A.C., Ryan C.H., Murray D.M., Eberwein D.J., et al. Adenocarcinoma cells exposed in vitro to navelbine or taxol increase Ep-CAM expression through a novel mechanism. Cancer Immunol. Immunother. (2003)
20. Gires O., Kieu C., Fix P., Schmitt B., Munz M., Wollenberg B., and Zeidler R. Tumour necrosis factor alpha negatively regulates the expression of the carcinoma-associated antigen epithelial cell adhesion molecule. Cancer 92 (2001) 620-628
21. Flieger D., Hoff A.S., Sauerbruch T., and Schmidt-Wolf I.G. Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression. Clin. Exp. Immunol. 123 (2001) 9-14
22. Ottaviano Y.L., Issa J.P., Parl F.F., Smith H.S., Baylin S.B., and Davidson N.E. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res. 54 (1994) 2552-2555
23. Yoshida T., Eguchi H., Nakachi K., Tanimoto K., Higashi Y., Suemasu K., et al. Distinct mechanisms of loss of estrogen receptor alpha gene expression in human breast cancer: methylation of the gene and alteration of trans-acting factors. Carcinogenesis 21 (2000) 2193-2201
24. Nass S.J., Herman J.G., Gabrielson E., Iversen P.W., Parl F.F., Davidson N.E., and Graff J.R. Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res. 60 (2000) 4346-4348
25. Widschwendter M., Berger J., Hermann M., Muller H.M., Amberger A., Zeschnigk M., et al. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J. Natl Cancer Inst. 92 (2000) 826-832
26. Graff J.R., Herman J.G., Lapidus R.G., Chopra H., Xu R., Jarrard D.F., et al. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55 (1995) 5195-5199
27. Graff J.R., Gabrielson E., Fujii H., Baylin S.B., and Herman J.G. Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J. Biol. Chem. 275 (2000) 2727-2732
28. Rice J.C., Massey-Brown K.S., and Futscher B.W. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 17 (1998) 1807-1812
29. Catteau A., Harris W.H., Solomon E., and Xu C.F. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18 (1999) 1957-1965
30. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Blake C., Shibata D., et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28 (2000) E32
31. Eads C.A., Danenberg K.D., Kawakami K., Saltz L.B., Danenberg P.V., and Laird P.W. CpG island hypermethylation in human colorectal tumours is not associated with DNA methyltransferase overexpression. Cancer Res. 59 (1999) 2302-2306
32. Eads C.A., Lord R.V., Kurumboor S.K., Wickramasinghe K., Skinner M.L., Long T.I., et al. Fields of aberrant CpG island hypermethylation in barrett's esophagus and associated adenocarcinoma. Cancer Res. 60 (2000) 5021-5026
33. Widschwendter M., and Jones P.A. DNA methylation and breast carcinogenesis. Oncogene 21 (2002) 5462-5482
34. Song S.H., Jong H.S., Choi H.H., Inoue H., Tanabe T., Kim N.K., and Bang Y.J. Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5′ CpG island in human gastric carcinoma cells. Cancer Res. 61 (2001) 4628-4635
35. Sharrard R.M., Royds J.A., Rogers S., and Shorthouse A.J. Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br. J. Cancer 65 (1992) 667-672
36. Mielnicki L.M., Ying A.M., Head K.L., Asch H.L., and Asch B.B. Epigenetic regulation of gelsolin expression in human breast cancer cells. Cell Res. 249 (1999) 161-176